NCT03861455View on ClinicalTrials.gov

Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

November 9, 2023

Study Completion Date

December 20, 2023

Conditions

Chronic Hand Eczema

Interventions

DRUG

Dupilumab

patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0

DRUG

placebo

patient receive placebo

Trial Locations (4)

30000

Saint André Hospital, Bordeaux

31059

Larrey Hospital, Toulouse

34000

Hôpital Saint Eloi, Montpellier

69495

CHU Lyon-Sud Département d'allergologie et d'immunologie clinique, Pierre-Bénite

All Listed Sponsors

lead

University Hospital, Toulouse

OTHER

NCT03861455 - Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids | Biotech Hunter | Biotech Hunter